文献速递胸部肿瘤

欧洲胸膜间皮瘤流行病学:欧洲胸部肿瘤平台Mesoscape数据库与欧洲胸外科医师学会间皮瘤数据库联合分析的真实世界数据

European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database.
PubMed 文献 · J Thorac Oncol · 2023-06-23

该研究联合分析欧洲胸部肿瘤平台Mesoscape数据库与欧洲胸外科医师学会(ESTS)间皮瘤数据库,纳入2766例胸膜间皮瘤(PM)患者,描述组织学亚型、分期与治疗模式,并评估总生存(OS)。中位随访47.2个月,中位OS为17.4个月;多因素分析中女性、上皮样亚型与较低分期与更长OS相关,Mesoscape队列中多学科治疗(含手术)与更长OS相关(HR=0.56,95%CI:0.45-0.69)。

要点

  • 2766例PM患者中上皮样亚型占71%,57%患者为III至IV期。
  • 中位随访47.2个月,中位OS为17.4个月。
  • Mesoscape队列中多学科治疗(含手术)与更长OS相关(HR=0.56,95%CI:0.45-0.69)。

核心结论

  • 该联合数据库分析反映接受多学科治疗(包括肉眼完全切除)的经选择患者存在获益,并为个体患者的流行病学与治疗选择提供资源。

研究设计与样本

  • 欧洲胸部肿瘤平台Mesoscape数据库与欧洲胸外科医师学会(ESTS)间皮瘤数据库的联合分析。
  • 共纳入2766例患者(Mesoscape:497例/10个中心;ESTS:2269例/77个中心)。

主要发现

  • 主要组织学亚型为上皮样(71%),57%患者处于III至IV期。
  • Mesoscape队列中患者接受多学科治疗(59%)或姑息意向治疗(41%)。
  • 中位随访47.2个月(基于1103例患者:Mesoscape 491例/ESTS 612例),共823例死亡,中位OS为17.4个月。
  • 多因素分析按队列、年龄和ECOG体能状态分层后,女性、上皮样亚型与较低分期与更长OS相关。
  • Mesoscape队列中,调整性别、组织学亚型与ECOG体能状态后,含手术的多学科治疗可预测更长OS(HR=0.56,95%CI:0.45-0.69)。

关键数值与推荐

  • 多学科治疗(含手术)与更长OS相关:HR=0.56(95%CI:0.45-0.69)。
  • 肉眼完全切除者中位OS为25.2个月,R2者为16.4个月(log-rank P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Pleural mesothelioma (PM) is an aggressive malignancy with increasing prevalence and poor prognosis. Real-life data are a unique approach to reflect the reality of PM epidemiology, treatment, and prognosis in Europe. METHODS: A joint analysis of the European Thoracic Oncology Platform Mesoscape and the European Society of Thoracic Surgeons (ESTS) databases was performed to better understand the characteristics and epidemiology of PM, including histologic subtype, staging, and treatment. Overall survival (OS) was assessed, adjusting for parameters of clinical interest. RESULTS: The analysis included 2766 patients (Mesoscape: 497/10 centers/ESTS: 2269/77 centers). The primary histologic subtype was epithelioid (71%), with 57% patients on stages III to IV. Within Mesoscape, the patients received either multimodality (59%) or palliative intention treatment (41%). The median follow-up was 47.2 months, on the basis of 1103 patients (Mesoscape: 491/ESTS: 612), with 823 deaths, and median OS was 17.4 months. In multivariable analysis, female sex, epithelioid subtype, and lower stage were associated with longer OS, when stratifying by cohort, age, and Eastern Cooperative Oncology Group Performance Status. Within Mesoscape, multimodality treatment including surgery was predictive of longer OS (hazard ratio = 0.56, 95% confidence interval: 0.45-0.69), adjusting for sex, histologic subtype, and Eastern Cooperative Oncology Group Performance Status. Overall, surgical candidates with a macroscopic complete resection had a significantly longer median OS compared with patients with R2 (25.2 m versus 16.4 m; log-rank p < 0.001). CONCLUSIONS: This combined European Thoracic Oncology Platform/ESTS database analysis offers one of the largest databases with detailed clinical and pathologic outcome. Our finding reflects a benefit for selected patients that undergo multimodality treatment, including macroscopic complete resection, and represents a valuable resource to inform the epidemiology and treatment options for individual patients.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Opitz I, Bille A, Dafni U, et al. European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database. J Thorac Oncol. 2023. PMID: 37356802. doi:10.1016/j.jtho.2023.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。